Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
These agents, known for their dual impact on both immune modulation and metabolic improvement, offer a unique therapeutic potential in managing immune-mediated inflammatory diseases ( 3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib ( Several studies have reported an inverse relationship between BMI and therapeutic efficacy, indicating that obesity may attenuate clinical responses to biologic disease modifying anti-rheumatic drugs (bDMARDs)
Es grande
These are not conservative estimates
Keywords: cardiorenal outcomes, chronic kidney disease, diabetes, obesity, nephroprotection Introduction Driven by both traditional and emerging non-traditional risk factors, the prevalence of chronic kidney disease (CKD) has increased significantly in recent years
US$ 24.80
US$ 28.37
US$ 24.62
US$ 29.79
US$ 25.96
US$ 26.26
